Massage Therapist Association of Alberta
There IS a Difference

POSITION AND GUIDELINES STATEMENT

THE USE AND SALE OF CANNABIS DERIVED PRODUCTS INCLUDING CBD

The Cannabis Act – Bill C-45, was recently passed by the Canadian Senate and is now in the final stages towards legislation. However it is important for all MTAA members to understand that during this phase, Cannabis is still considered a Controlled Schedule ll Drug, which means it is illegal. According to The Controlled Drugs and Substances Act (S.C. 1996, c. 19) Cannabis and its derivatives are specifically defined as (an excerpt):

1 Cannabis, its preparations and derivatives, including:
(1) Cannabis resin
(2) Cannabis (marihuana)
(3) Cannabidiol (2–[3–methyl–6–(1–methylethenyl)–2–cyclohexen–1–yl]–5–pentyl–1,3–benzenediol)
(4) Cannabinol (3–n–amyl–6,6,9–trimethyl–6–dibenzopyran–1–ol)
(7) Tetrahydrocannabinol (tetrahydro–6,6,9–trimethyl–3–pentyl–6H–dibenzo[b,d]pyran–1–ol)
(http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-13.html#docCont)

Currently, all CBD (Cannabidiol) containing products are classified as a Schedule II Drug, including CBD lubricants. The use of any CBD related product as a lubricant, by a Massage Therapist, can be interpreted as ‘dispensing’ and is beyond the Scope of Practice for Massage Therapists. Until Cannabis is fully legalized in Canada, only Licensed Producers (LPs) approved by Health Canada can legally sell Cannabis products including Cannabidiol products, to medically prescribed users.

The MTAA strongly advises its members to observe the laws related to Cannabis use, sale, and acquisition, and refrain at this time, from using any such products in their practice.

The following guidelines apply to ALL MTAA members:

  1. DO NOT USE any products, or apply any lubricants, that contain any amounts of CBD or THC (tetrahydrocannabinol), regardless of the source of these compounds, in your clinical environment in the course of providing treatment as a Massage Therapist.
  2. DO NOT SELL any products that contain any amounts of CBD or THC, regardless of the source of these compounds, in your clinical environment unless you are an approved Licensed Producer by Health Canada.
  3. DO NOT RECOMMEND any products that contain any amounts of CBD or THC, regardless of the source of these compounds, to any persons /clients in your clinical practice.

Once Cannabis becomes legal, The Cannabis Act will influence potential changes to other legislation.  However, at this time there is no definitive knowledge as to precisely how legalization of Cannabis will fully affect The Controlled Drugs and Substances Act and related Schedules.  The MTAA will keep our members apprised as additional information becomes available.

To Download a Hard Copy of this Position Statement and Guideline, click here.


The MTAA is in the process of creating information-based workshops designed to provide our members with an awareness and understanding of the legislation surrounding Cannabis both from a medicinal as well as a recreational perspective. 

In order to assist us in the creation of these workshops, we would greatly appreciate your input by way of an online survey related to Cannabis awareness.  To complete the survey, please click the link below or copy and paste it into your browser window:  https://www.surveymonkey.com/r/Cannabis_Aware